# EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients

> **NCT02443688** · PHASE2 · COMPLETED · sponsor: **Celtaxsys, Inc.** · enrollment: 200 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** CTX-4430
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02443688
- **Lead sponsor:** Celtaxsys, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-30
- **Primary completion:** 2018-04-20
- **Final completion:** 2018-05-16
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2019-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02443688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02443688, "EMPIRE CF: A Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of CTX-4430 in Adult Cystic Fibrosis (CF) Patients". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT02443688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*